HLA gene polymorphism among Bangladeshi patients with end-stage renal disease awaiting kidney transplantation

Afzalunnessa, Sharmin Sultana, Shahina Tabassum

Introduction

Organ transplantation is considered as life enhancing and technologically advanced therapy now-a-days. Renal transplantation is the most standard and successful therapy for the end stage renal disease (ESRD). Compatibility of human leukocyte antigens (HLA) among the recipient and donor is an important prerequisite for the long survival of a transplanted organ. To reveal the HLA gene polymorphism among end-stage renal disease (ESRD) patients and their donors, a total of 180 ESRD patients and 320 donors, referred by clinicians for HLA typing, were included in this study. HLA typing was performed using Polymerase Chain Reaction-Sequence Specific Primer (PCR-SSP). The most frequent alleles reported from both groups were, A*11, A*02 and A*33 in A locus; B*15:02, B*35 and B*52 in B locus and DRB1*15, DRB1*07 and DRB1*04 in DR locus. Frequencies of four alleles, A*26, B*57, B*40 and DRB1*11 were found to be higher in ESRD patients. The three locus haplotypes A*24, B*15:02, DRB1*15 were observed more frequently among recipients than in donors. The results were found to be in genetic equilibrium. Higher frequencies of certain alleles in recipients may be indicative of risk factor for renal disease. Further studies are needed to corroborate the findings of this study.

Abstract

Proper matching of HLA class I and class II antigens among donor and recipient is an important prerequisite for the long survival of a transplanted organ. To reveal the HLA gene polymorphism among end-stage renal disease (ESRD) patients and their donors, a total of 180 ESRD patients and 320 donors, referred by clinicians for HLA typing, were included in this study. HLA typing was performed using Polymerase Chain Reaction-Sequence Specific Primer (PCR-SSP). The most frequent alleles reported from both groups were, A*11, A*02 and A*33 in A locus; B*15:02, B*35 and B*52 in B locus and DRB1*15, DRB1*07 and DRB1*04 in DR locus. Frequencies of four alleles, A*26, B*57, B*40 and DRB1*11 were found to be higher in ESRD patients. The three locus haplotypes A*24, B*15:02, DRB1*15 were observed more frequently among recipients than in donors. The results were found to be in genetic equilibrium. Higher frequencies of certain alleles in recipients may be indicative of risk factor for renal disease. Further studies are needed to corroborate the findings of this study.
Methods

Study Participants: A total of 180 adults with ESRD and 320 healthy individuals, advised for their HLA typing, were included in this study. All related information was obtained from the record registry of the laboratory. As age and gender does not influence an individual’s HLA profile, the control group was not age and gender-matched with the patient group. Their mean age was 35±10.2 with lowest age 18 and highest 68 years.

DNA extraction: Five ml of whole blood samples were collected in ethylene diaminetetraacetic acid (EDTA) containing vial for DNA extraction and stored at -20°C. Purified genomic DNA was extracted using EZ-10 Spin Column Genomic DNA extraction kit (Bio Basic Inc, Canada) according to manufacturer instructions. The purity and concentration of the DNA was estimated using NanoDrop1000 spectrophotometer (Thermo scientific) and stored at -20°C until tested.

HLA-A, -B and -DRB1 Typing by Sequence Specific Primer based Polymerase Chain Reaction (PCR-SSP): HLA typing was carried out for 23 alleles of A, 40 alleles of B and 16 alleles of DRB1 locus, using PCR-SSP HLA kit (Micro SSPTM Generic HLA Class I and Class II DNA Typing Tray, One Lambda Inc., Canoga Park, CA). Amplification was done by thermal cycler GeneAmp PCR system 9700 (Applied Biosystems, USA). The amplified products were visualized and photographed under UV transillumination after 2% agarose gel electrophoresis. HLA alleles were assigned on the basis of the presence of allele specific bands in the gel. Interpretation of the results was carried out using the worksheets of HLA-A, HLA-B, and HLA-DR provided by the manufacturer.

Allele frequencies of HLA-A, -B and -DRB1 were calculated by the direct counting method. Two locus and three locus haplotype frequencies and genotype frequencies of HLA-A, -B and -DRB1 locus were determined by Hardy-Weinberg equilibrium test. Linkage disequilibrium (LD) and normalized linkage disequilibrium between two locus haplotype were calculated by the method of Lewontin. [8-9] HLA-A, -B, -DRB1 allele’s frequencies and HLA-A-B-DRB1 haplotypes were compared between ESRD patients and controls by Pearson chi-square test. A 5% significance level was considered sufficient to reject the null hypothesis.

Results

A total of 17 alleles of A, 24 of B, 14 of DRB1 locus were detected from ESRD patients and 16 of A, 25 of B and 14 of DRB1 locus were detected from donors group (Tables-1- 3). On data analysis, allele frequency of A, B and DR loci did not differ significantly among patients and donors. The most frequent alleles found in both groups of HLA-A locus were

| Table I |
|---------------------------------------------|
| **Allele frequency of HLA-A locus in end stage renal disease (ESRD) patients and donors (N=500)** |

| HLA-A | Patients (n=180) | Donors (N=320) | Odd Ratio (OR) |
|-------|------------------|----------------|---------------|
|       | Number | Antigen Frequency | Number | Antigen Frequency |       |
| A*11  | 74     | 20.56           | A*11  | 159     | 24.84 | 0.78     |
| A*02  | 65     | 18.06           | A*02  | 102     | 15.94 | 1.16     |
| A*33  | 59     | 16.39           | A*33  | 95      | 14.84 | 1.12     |
| A*24  | 57     | 15.83           | A*24  | 89      | 13.91 | 1.15     |
| A*01  | 35     | 9.72            | A*01  | 57      | 8.91  | 1.10     |
| A*68  | 19     | 5.28            | A*68  | 41      | 7.34  | 0.81     |
| A*03  | 15     | 4.17            | A*03  | 47      | 6.41  | 0.54     |
| A*26  | 11     | 3.06            | A*26  | 10      | 1.56  | 1.99     |
| A*30  | 9      | 2.5             | A*30  | 13      | 2.03  | 1.23     |
| A*31  | 8      | 2.22            | A*31  | 17      | 2.66  | 0.83     |
| A*25  | 3      | 0.83            | A*25  | 2       | 0.31  |           |
| A*29  | 2      | 0.56            | A*29  | 2       | 0.31  |           |
| A*36  | 2      | 0.56            | A*32  | 2       | 0.31  |           |
| A*74  | 1      | 0.28            | A*74  | 1       | 0.16  |           |
| A*25  | 1      | 0.28            | A*25  | 1       | 0.16  |           |
|       | 1      | 0.16            | A*36  | 1       | 0.16  |           |
|       |        |                 | A*69  |         |       |           |
A*11, A*02 and A*33 (20.56%, 18.06%, 16.36% and 24.84%, 15.95%, 14.84% respectively) followed by A*24, A*01 and A*68. Moreover, A*74, A*29 and A*36 were found to be rare and in both groups with a frequency of less than 1%. However, the common alleles in B locus found B*15:02, B*35, B*52 and B*44 with a frequency of greater than 8% in both groups. The least frequent allele observed were B*39, B*49, B*78, B*40:01 (Table-2). The polymorphism of DR locus revealed DRB1*15, DRB1*07, DRB1*04 and DRB1*12 as most frequent alleles in both groups (Table-3). However, allele comparison among the two groups revealed a positive association of ESRD with A*26 (OR:1.99), A*30 (OR:1.29), B*57 (OR:1.54). DRB1*11 (OR:1.69), DRB1*12 (OR:1.52) and a negative association with A*03 (OR:0.54), B*51 (OR:0.52), B*40:02 (OR:0.57), but the differences were not statistically significant (P value >0.05).

Haplotype analysis of the two loci (HLA-A and B) revealed 116 variation in patients and 138 variation in donors with two most frequent haplotypes A*11: B*15:02 and A*33: B*44 in both groups, followed by A*02: B*15:02, A*33: B*15:02, A*24: B*35 and A*11: B*35 in patients and A*11: B*35, A*02: B*35, A*11: B*52 in donors. The first 15 two locus haplotypes of both groups with a frequency of more than 1.5% is shown in Tables-4.

### Table-II

| HLA-B   | Patients (N=180) | Donors (N=320) | Odd Ratio (OR) |
|---------|------------------|----------------|----------------|
|         | Number | Antigen | HLA-B | Number | Antigen | Frequency | Frequency |
| B*15:02 | 72 | 20 | B*15:02 | 109 | 17.03 | 1.21 |
| B*35    | 49 | 13.61 | B*35 | 92 | 14.38 | 0.93 |
| B*44    | 32 | 8.89 | B*44 | 71 | 11.09 | 0.78 |
| B*52    | 34 | 9.44 | B*52 | 55 | 8.59 | 1.1 |
| B*40:02 | 17 | 4.72 | B*40:02 | 51 | 7.97 | 0.57 |
| B*51    | 10 | 2.78 | B*51 | 33 | 5.16 | 0.52 |
| B*57    | 27 | 7.5 | B*57 | 32 | 5 | 1.54 |
| B*07    | 19 | 5.28 | B*07 | 31 | 4.84 | 1.09 |
| B*37    | 13 | 3.61 | B*37 | 25 | 3.91 | 0.92 |
| B*13    | 16 | 4.44 | B*13 | 24 | 3.75 | 1.19 |
| B*38    | 16 | 4.44 | B*38 | 22 | 3.44 | 1.3 |
| B*15:01 | 16 | 4.44 | B*15:01 | 21 | 3.28 | 1.37 |
| B*40:01 | 5 | 1.39 | B*40:01 | 18 | 2.81 | |
| B*27    | 8 | 2.22 | B*27 | 16 | 2.5 | |
| B*58    | 8 | 2.22 | B*58 | 11 | 1.72 | |
| B*18    | 3 | 0.83 | B*18 | 9 | 1.41 | |
| B*08    | 1 | 0.28 | B*08 | 5 | 0.78 | |
| B*55    | 6 | 1.67 | B*55 | 4 | 0.63 | |
| B*56    | 2 | 0.56 | B*56 | 3 | 0.47 | |
| B*15:17 | 1 | 0.28 | B*63 | 3 | 0.47 | |
| B*39    | 1 | 0.28 | B*39 | 1 | 0.16 | |
| B*78    | 2 | 0.56 | B*78 | 1 | 0.16 | |
| B*45    | 1 | 0.28 | B*45 | 1 | 0.16 | |
### Table-III

Allele frequency of HLA-B locus among study participants (N=500)

| HLA-B   | Number | Frequency | Antigen | HLA-B   | Number | Frequency | Antigen | Odd Ratio |
|---------|--------|-----------|---------|---------|--------|-----------|---------|-----------|
| DRB1    |        |           |         | DRB1    |        |           |         |           |
| DR*15   | 137    | 38.06     | DRB1*15 | 216     | 33.75  | 1.20      |
| DR*07   | 57     | 15.83     | DRB1*07 | 129     | 20.16  | 0.74      |
| DR*04   | 34     | 9.44      | DRB1*04 | 79      | 12.34  | 0.74      |
| DR*12   | 42     | 11.67     | DRB1*12 | 51      | 7.97   | 1.52      |
| DR*10   | 27     | 7.5       | DRB1*10 | 45      | 7.03   | 1.07      |
| DR*01   | 11     | 3.06      | DRB1*01 | 23      | 3.59   | 0.84      |
| DR*13   | 11     | 3.06      | DRB1*13 | 21      | 3.28   | 0.93      |
| DR*1404 | 9      | 2.5       | DRB1*1404 | 19 | 2.97 | 0.83 |
| DR*11   | 15     | 4.17      | DRB1*11 | 16      | 2.5    | 1.69      |
| DR*03   | 6      | 1.67      | DRB1*03 | 13      | 2.03   | 0.81      |
| DR*14   | 6      | 1.67      | DRB1*14 | 11      | 1.72   |           |
| DR*09   | 1      | 0.28      | DRB1*09 | 9       | 1.41   |           |
| DR*16   | 3      | 0.83      | DRB1*16 | 6       | 0.94   |           |
| DR*08   | 1      | 0.28      | DRB1*05 | 1       | 0.16   |           |

### Table-IV

Two locus haplotype (HLA-A and B) frequencies (>0.015) among study participants (N=500)

| HLA-A   | HLA-B | Number | Frequency | HLA-A   | HLA-B | Number | Frequency |
|---------|-------|--------|-----------|---------|-------|--------|-----------|
| A*11    | B*15:02 | 17     | 0.047222  | A*11    | B*15:02 | 42     | 0.065625  |
| A*33    | B*44   | 16     | 0.044444  | A*33    | B*44   | 27     | 0.042188  |
| A*2     | B*15:02 | 12     | 0.033333  | A*11    | B*35   | 21     | 0.032813  |
| A*33    | B*15:02 | 12     | 0.033333  | A*2     | B*35   | 20     | 0.031250  |
| A*24    | B*35   | 11     | 0.030556  | A*11    | B*52   | 18     | 0.028125  |
| A*11    | B*35   | 11     | 0.030556  | A*3     | B*35   | 17     | 0.026563  |
| A*2     | B*38   | 10     | 0.027778  | A*33    | B*15:02 | 17     | 0.026563  |
| A*11    | B*52   | 9      | 0.025000  | A*2     | B*15:02 | 15     | 0.023438  |
| A*24    | B*15:02 | 9      | 0.025000  | A*11    | B*44   | 12     | 0.018750  |
| A*11    | B*44   | 7      | 0.019444  | A*11    | B*40:02 | 12     | 0.018750  |
| A*2     | B*35   | 7      | 0.019444  | A*24    | B*15:02 | 12     | 0.018750  |
| A*33    | B*57   | 6      | 0.016667  | A*24    | B*35   | 11     | 0.017188  |
| A*2     | B*7    | 6      | 0.016667  | A*24    | B*40:02 | 11     | 0.017188  |
| A*1     | B*15:02 | 6      | 0.016667  | A*2     | B*7    | 10     | 0.015625  |
| A*31    | B*15:02 | 6      | 0.016667  | A*2     | B*40:2 | 10     | 0.015625  |
Three locus haplotype (A and B locus of MHC class I and DRB1 locus of MHC class II gene) analyses observed 236 and 320 variations of haplotypes among patients and donors respectively. The first 20 variations found A*11: B*15:02: DRB1*15 was the most frequent haplotypes in both groups. Among the recipient group, A*24: B*15:02:DRB1*15 was the second most frequent haplotype, followed by A*11: B*52:DRB1*15, A*33: B*44: DRB1*15 and A*33: B*15:02: DRB1*15. Moreover, among donor group, A*33: B*44: DRB1*07, A*33: B*44: DRB1*15, A*02: B*35: DRB1*07, A*11: B*15:02: DRB1*12 were the haplotypes after the most frequent one (Table-V).

### Table-IV

| Haplotypes (A:B:DRB1) | Number | Observed frequency | Haplotypes (A:B:DRB1) | Number | Observed frequency |
|------------------------|--------|--------------------|------------------------|--------|--------------------|
| *11:*15:02:*15         | 9      | 0.025              | *11:*15:02:*15         | 23     | 0.0359             |
| *24:*15:02:*15         | 8      | 0.0222             | *33:*44:*07            | 10     | 0.0156             |
| *11:*52:02:*15         | 7      | 0.0194             | *02:*35:*07            | 9      | 0.0141             |
| *33:*44:*15            | 6      | 0.0167             | *33:*15:02:*15         | 9      | 0.0141             |
| *33:*15:02:*15         | 6      | 0.0167             | *11:*44:*07            | 8      | 0.0125             |
| *11:*15:02:*12         | 5      | 0.0139             | *11:*52:*15            | 8      | 0.0125             |
| *02:*38:*15            | 5      | 0.0139             | *11:*40:02:*15         | 8      | 0.0125             |
| *02:*15:02:*12         | 5      | 0.0139             | *11:*15:02:*12         | 8      | 0.0125             |
| *02:*15:02:*15         | 5      | 0.0139             | *24:*40:02:*15         | 7      | 0.0109             |
| *31:*15:02:*15         | 5      | 0.0139             | *02:*15:02:*15         | 7      | 0.0109             |
| *33:*44:*07            | 5      | 0.0139             | *33:*44:*15            | 6      | 0.0094             |
| *26:*52:*15            | 4      | 0.0111             | *03:*35:*15            | 6      | 0.0094             |
| *33:*57:*15            | 4      | 0.0111             | *68:*52:*15            | 6      | 0.0094             |
| *33:*40:02:*15         | 4      | 0.0111             | *11:*35:*15            | 5      | 0.0078             |
| *11:*35:*15            | 3      | 0.0083             | *01:*44:*07            | 5      | 0.0078             |
| *11:*37:*10            | 3      | 0.0083             | *24:*40:01:*15         | 5      | 0.0078             |
| *11:*44:*04            | 3      | 0.0083             | *24:*15:02:*15         | 5      | 0.0078             |
| *11:*44:*07            | 3      | 0.0083             | *02:*35:*15            | 5      | 0.0078             |
| *01:*37:*10            | 3      | 0.0083             | *02:*44:*07            | 5      | 0.0078             |
| *01:*75:*12            | 3      | 0.0083             | *11:*35:*12            | 4      | 0.0062             |

Allele frequencies of HLA-A-A, HLA-B-B and HLA-DRB1 genotype in patients group showed that the highest frequency for HLA-A antigens were A11: A33, A2: A33, A1: A11, for HLA-B antigens were B75: B75, B35: B44, B35: B75 and for HLA-DR antigens were DR7: DR15, DR15: DR15, DR4: DR15 respectively. Among the donor group, HLA-A, HLA-B and HLA-DR were A2: A11, A11: A11, A11: A24; B35: B75, B75: B75, B44: B75; DR7: DR15, DR15: DR15, DR4: DR15 respectively (Figure 1-3).
**Figure - 1:** HLA A-A antigen frequencies among patients and donors.

**Figure - 2:** HLA B-B antigen frequencies bar plot of patients and donors.
Figure - 3: HLA DRB1-DRB1 antigen frequencies bar plot of patients and donors

Discussion

HLA molecules play a major role in regulation of the body’s immune system by detecting self from non-self antigen and are thus considered as the major barrier for successful organ transplantation. The success of graft survival depends largely on well matching of HLA antigens of patient and donor. For this, analyses of HLA distribution patterns is necessary for the estimation of the likelihood of obtaining matched donors to increase the graft survival rate. Moreover, HLA system has been found to be associated with the pathogenesis of some renal diseases like, IgA nephropathy, glomerulonephritis, diabetic nephropathy and some autoimmune diseases and inflammatory bowel diseases. Thus, identification and analysis of the HLA polymorphism in ESRD patients is also important for the determination of a possible association of the disease with HLA system.

In this study, among ESRD patients and donors, A, B and DRB1 locus were found to be similar and both groups were in genetic equilibrium. The highest frequent allele detected in A, B and DRB1 locus of patients- A*11, B*15:02 and DRB1*15 were also reported highest among donors of this study. Not only the highest one, the first four most frequent alleles of each three loci; A*11, A*02, A*33, A*24 of A, B*15:02, B*35, B*44, B*52 of B and DRB1*15, DRB1*07, DRB1*04, DRB1*12 of DRB1 locus were found to be in agreement within both groups. Additionally, these highest frequent alleles were also be reported highest from a previous study, as well as from another population based study from Bangladesh. As cadaveric transplant has not yet started in Bangladesh, most of the donors of this study were blood relatives of the patients. Moreover, racial diversity is less frequent in the Bangladeshi population, which may be the underlying cause of similar pattern of allele distribution among donors and patients. However, the relative occurrence of allele frequencies had shown some differences. The ESRD patients group had higher frequencies of A*26 (OR:1.99), A*30(OR:1.29), B*57(OR:1.54), B*15:01(OR:1.37) and DRB1*11(OR:1.69) compared to the donor group. On the other hand, HLA A*03(OR: 0.54), B*51(OR:0.52) and B*40:02(OR:0.57) was observed less frequently among recipients than donors. Although these findings are not statistically significant, it may suggest some association of HLA alleles with the development of ESRD. DRB1*11, which was observed more frequent among ESRD patients from Taiwan, was also reported significantly higher among ESRD patients from Taiwan. A significant association with renal diseases of different A and B locus alleles were also reported from China, Iran, Arab, Egypt and Kuwait. A positive association and protective role of some alleles was also reported from Venezuela. However, the positively associated alleles from different countries are not
unique in distribution. This diversity in the findings of different researchers may be due to the irregularity in allele frequency among different ethnic groups and geographical locations.

Marked difference in allelic distribution of different loci in different ethnic population may be due to the extreme polymorphism of major histocompatibility complex (MHC) genes. Thus, comparison of HLA genotypes among different populations may be important because the probability of incompatibility at the allele level will be affected by different origins of recipients and donors. For this reason, we compared the more frequently observed alleles from this study with the findings of similar studies from surrounding Asian population and found it to be comparable with alleles detected among donors and recipients from Nepal different states of India and Pakistan, and Mayanmar and other oriental people of South Asian countries like China, Thailand, Malaysia and Vietnam. However, when compared with the world population, frequently reported alleles of Asian people were observed to be less frequent in Hispanics, Caucasians and North African population.

In this study, analysis of antigen expression of HLA-A-A, B-B and DRB1-DRB1 genotype revealed higher frequency of A11/A33, B75/ B75 and B35/ B44 antigens in patients (0.10, 0.056, 0.050) compared to donors (0.06, 0.045, 0.030). These findings suggest that these types may have some association with renal disease. A study from West Central India also reported variations in antigen distribution among donors and recipients. A review of different HLA and renal disease associated studies summarized possible protective and risk associated alleles of A, B and DRB1 locus. However, there are marked variation of HLA antigen distribution among different ethnicity and geographical location, thus, protective and risk antigen will also be varied accordingly, but this issue needs further investigation.

HLA haplotype carries more specific information than HLA allele frequencies. In this study, the most common haplotypes observed in the two locus HLA-A- B haplotype were A*11-B*15:02 and A*33- B*44 with a frequency of 0.065 and 0.042, respectively among donors and 0.047 and 0.044, respectively among patients. The A*11- B*15:02 haplotype is predominant among Mayanmar Rakhain, Mayanmar Kayah as well as other Asian people, including Sri-Lanka, Malaysia Peninsular Malay and Oriental people of South East Asian countries including Vietnam and China. Moreover, the common three locus haplotypes, A*11- B*15:02-DRB1*15 distribution observed in this present study has also been reported frequent from Mayanmar Rakhine population and other oriental people. In Uttar Pradesh (North India), A2-B7; A3-B51 was found the common alleles in both renal transplant recipients and donors (North India); A2-B40; A9-B35 was common in Maharasstra (Western India); A*02-B*61; A*01-B*57 was common in west central India; A*24, B*35, DRB1*15 was common in Telangana and Andhra Pradesh, while among the Bengali population of Siliguri and adjoining areas of West Bengal, A*01-B*37; A*01-B*40, A*29-B*40 was common. All of these reported haplotypes were found to be less frequent in this study as well as in our previous study. Haplotype analysis of this study indicates that Bangladeshi people have more influence of the Oriental people than Caucasoid.

The result of this study suggests that a wide variety of HLA antigen distribution is present in ESRD patients and donors in Bangladesh. Many immune suppressive drugs are used to prevent graft rejection, but HLA matching plays the vital role in graft survival rate. A study on the effect of HLA-A, -B and -DR matching on survival of adult renal transplant recipients by analyzing the records of 189141 adult transplant patients who had received organs from deceased donors found that the hazard ratios are significantly linear for HLA mismatch. Bangladesh is planning to start cadaver transplant very soon. If haplotype identical cadaver renal transplant is required, large registries are to be created for end stage renal disease patients. The data of this study will be helpful in creating a national registry and organ sharing network for Bangladesh. In addition to renal transplant, patients in need of hematopoietic stem cell transplantation will also benefit by finding suitable donors.

Conclusion

Haplotype and allele frequency observed in this study indicates that both patients and donor groups are in genetic equilibrium. Higher frequency of some alleles found in patients and donors may have some susceptible and protective role in end stage renal disease development. However, none of these were found to be significant statistically. Further studies are needed to corroborate the findings of this study.

Acknowledgement

We thank Afroza Parveen Dolly and Fatema for their technical support. In addition, we acknowledge the kind cooperation of the patients and donors.

Conflict of Interest : None

Funding Agency : None

References

1. McCluskey J, Peh CA. The human leucocyte antigens and clinical medicine: an overview. Rev Immunogenet . 1999; 1:3–20.
2. Shankarkumar U. Complexities and similarities of HLA antigen distribution in Asian subcontinent. Indian J Hum Genet. 2010; 16(3): 108-10.

3. Ayala García MA, Gonzalez Yebra B, Lopez Flores AL, Guani Guerra E. The major histocompatibility complex in transplantation. J Transplant. 2012; 2012: 842141.

4. Ahmad T, Marshall SE, Jewell D. Genetics of inflammatory bowel disease: the role of the HLA complex. World J Gastroenterol 2006; 12:3628-35.

5. Kallaur AP, Kaimen-Macieł DR, Morimoto HK, Watanabe MA, George-To SM, Reiche EM. Genetic polymorphisms associated with the development and clinical course of multiple sclerosis (review). Int J Mol Med 2011; 28:467-79.

6. Vuong MT, Lundberg S, Gunnarsson I, Wramner L, Lundstrom E, Fernstrom A, et al. Genetic evidence for involvement of adaptive immunity in the development of IgA nephropathy: MHC class II alleles are protective in a Caucasian population. Hum Immunol 2013; 74:957-60.

7. Dai CS, Chu CC, Chen SF, Sun CY, Lin M, Lee CC. Association between human leucocyte antigen subtypes and risk of end stage renal disease in Taiwanese: a retrospective study. BMC Nephrol 2015; 16:177.

8. Lewontin RC and Kojima K. The evolutionary dynamics of complex polymorphisms. Evolution. 1960;14, 458-472.

9. Lewontin RC. The interaction of selection and linkage. I. General considerations; heterotic models. Genetics. 1964; 49: 49-67.

10. Sultana S, Tabassum S, Nessa A. Human Leukocyte Antigen: Class I Allele Frequencies and Haplotype Distribution in a Tertiary Care Hospital in Bangladesh. Bangladesh Med Res Counc Bull. 2018; 44: 01-08.

11. Ali EM, Ahmed MU, Alam S, Rahman MH. HLA class II allele frequencies in the Bangladeshi population. Tissue Antigen. 2008; 72: 115-19.

12. Dai CS, Chu CC, Chen SF, Sun CY, Lin M and Lee CC. Association between human leucocyte antigen subtypes and risk of end stage renal disease in Taiwanese: a retrospective study. BMC Nephrol 2015; 16:177.

13. Cao Q, Xie D, Liu J, Zou H, Zhang Y, et al. HLA Polymorphism and Susceptibility to End-Stage Renal Disease in Cantonese Patients Awaiting Kidney Transplantation. PLoS ONE. 2014; 9(3): e90869. doi:10.1371/journal.pone.0090869

14. Davood PP, Farhadi N, Najafizadeh M. Protective and Susceptible HLA Class I genes in patients with end-stage renal disease. Res J Biol Sci. 2008; 3:1344–46.

15. Al-Taie LH, Al-Ghurabi BH, Al-Hassan AA, Dager AJ. Frequency of HLA-A and B antigens in Iraqi patients with end-stage renal disease preparing for transplantation. Iraqi Postgraduate Med J. 2012; 11:642–48.

16. El-Gezawy EM, Baset HA, Nasif KA et al. Human leukocyte antigens as a risk factor for the primary diseases leading to end stage renal disease in Egyptian patients. Egypt J Immunol. 2011; 18(2):13-21.

17. Mosaad YM, Mansour M, Al-Muzairai I, Al-Obaidi T, Abdul-Moneam M, Al-Attiyah R et al. Association between Human Leukocyte Antigens (HLA-A, -B, and -DR) and end-stage renal disease in Kuwaiti patients awaiting transplantation. Renal Failure. 2014;36:8, 1317-21.

18. Rivera S, Marquez G, Cipriani AM, Hassanhi M, Villalobos CC, Feunmayor A, Chavez M, Montiel M. HLA class I association with progression to end-stage renal disease in patients from Zulia, Venezuela. Immunologia. 2012; 31(2):37-42.

19. Tiercy JM. Molecular basis of HLA polymorphism: implications in clinical transplantation. Transpl Immunol. 2002; 9(2-4):173-80.

20. Tuladhar A, Shrestha S, Raut PP, Bhandari P, Shrestha P. HLA Antigen distribution in Renal Transplant Recipients and Donors. J Nepal Health Res Counc. 2013; 11:289-92.

21. Moatter T, Aban M, Tabassum S, Shaikh U, Pervez, S. Molecular analysis of human leukocyte antigen class I and class II allele frequencies and haplotype distribution in Pakistani population. Indian J Hum Genet. 2010; 16(3): 149-53.

22. Raza A, Firasat S, Khalaq S, Abid A, Shah SS, Mehdi SQ et al. HLA class I and II polymorphisms in the Gujar population from Pakistan. Immunol Invest. 2013; 42(8): 691-700.

23. Farjadian SN, Nasrue T, Kawata H, Ghaderi A, Bahram S, Inoko H. Molecular analysis of HLA allele frequencies and haplotypes in Baloch of Iran compared with related populations of Pakistan. Tissue Antigens. 2004; 64:581-87.

24. Kongmaroeng, C., Romphruk, A., Puapairoj, C., Leelayuwat, C., Kulski, J.K., Inoko, H., Dunn, D.S. & Romphruk, A.V. HLA alleles and haplotypes in Burmese (Myanmarese) and Karen in Thailand. Tissue Antigens. 2015; 86, 199-04.

25. Zhou X-Y, Zhu F-M, Li J-P, Mao W, Zhang D-M, Liu M-L, et al. HLA class I and II allele frequencies and haplotype distribution in Myanmarese and Karen in Thailand. Tissue Antigens. 2005; 691-700.

26. Zhou X-Y, Zhu F-M, Li J-P, Mao W, Zhang D-M, Liu M-L, et al. High-Resolution Analyses of Human Leukocyte Antigens Allele and Haplotype Frequencies Based on 169,995 Volunteers from the China Bone Marrow Donor Registry Program. PLoS ONE. 2015; 10(9): e0139485.

27. Kuptawintu P, Pheacharoen S, Srisuddee A, Tanaka H, Tadokoro K, Nathalang O. HLA-A, -B, -DR haplotype frequencies in the Thai Stem Cell Donor Registry. Tissue Antigens. 2010; 75(6):730–36.

28. Teh K, Bee P C, Mohamed Z, Zain S M, Eng H S. HLA Antigen and Haplotype Distribution in Malaysian Candidates for Hematopoietic Stem Cell Transplantation. Poster Presentation Asia-Pacific Histocompatibility and Immunogenetics Association. 2018; 216665
28. Hoa BK, Hang NTL, Kashiwase K, Ohashi J, Lien LT, Horie T et al. HLA-A, -B, -C, -DRB1 and -DQB1 alleles and haplotypes in the Kinh population in Vietnam. Tissue antigens. 2008 Feb 1; 71(2):127-34.

29. Gonzalez-Galarza FF, Takeshita LY, Santos EJ, Kempson F, Maia MH, Silva AL, Silva AL, Ghattaoraya GS, Alfrevic A, Jones AR and Middleton D. Allele frequency net 2015 update: new features for HLA epitopes, KIR and disease and HLA adverse drug reaction associations. Nucleic Acid. 2015; 28: 784-88.

30. Patel JS, Patel MM, Koringa PG, Shah TM, Patel AK, Tripathi AK, et al., Human leukocyte antigen alleles, genotypes and haplotypes frequencies in renal transplant donors and recipients from West Central India. Indian J Hum Genet. 2013; 19:219-32.

31. Robson K J, Ooi J D, Holdsworth S R, Rossjohn J, Kitching A R. HLA and kidney disease: from associations to mechanisms. Nature Reviews | Nephrology. 2018; 14: 636-55.

32. Malavige GN, Rostron T, Seneviratne SL, Fernando S, Sivayogan S, Wijewickrama A & Ogg GS. HLA analysis of Sri Lankan Sinhalese predicts North Indian origin. International Journal of Immunogenetics. 2007; 34: 313-15.

33. Agrawal S, Singh AK, Sharma PK. HLA gene and haplotype frequency in renal transplant recipients and donors of Uttar Pradesh (North India). Indian J Nephrol. 2001; 11:88-97.

34. Chhaya SU, Shankarkumar U. HLA antigen distribution in Jain population from Mumbai, Maharashtra, India. Ind J Med Res. 2001; 114: 25-29.

35. Radhika chowdary D, Sukrutha Gopal R, Reddy VS, Pavani, Prasad Reddy K. Analysis of HLA-A, HLA-B and HLA-DRB1 allelic frequencies in tertiary care from Telangana and Andhra Pradesh. J Med Sci Res. 2014; 2(3):140-44.

36. Singh B, Mallick GC, Bandopadhyay S, Nayak CR, Chaudhuri TK. Study of Selected HLA-A and -B Antigens by PCR-SSP Method in Bengali Population of Siliguri and Adjoining Areas of West Bengal. Int J Hum Genet.2009; 9(3-4): 245-49.

37. Williams RC, Opelz G, McGarvey CJ, Weil EJ, Chakkera HA. The risk of transplant failure with HLA mismatch in first adult kidney allografts from deceased donors. Transplantation. 2016;100: 1094-102.